Genfit S.A. ADR (GNFT) Stock Price, Quote & News

Company Profile

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 20 16 40 00

Fax: 33 2 20 16 40 01

Website: www.genfit.com

Address:

Parc EurasantE, 885, avenue EugEne AvinEe, Loos, France

Thorilium Apr. 25 at 7:07 AM

$GNFT This happens when a stock is rejected This did not happened with $ABVEF Think why is this! Because the race is still open, just a few missed corners.

0 · Reply

Rickycello Feb. 25 at 12:10 PM

$GNFT bear: 6.78€ base: 10.26€ bull: 15€ Intrinsic value: 3.93€ Sell price target: 10.51€ (12% margin) Reward / risk: 0.39 Risk / reward: 2.54

0 · Reply

Alexis348 Feb. 24 at 6:33 PM

$GNFT what's everyones thought on this. How far up can it go?!

1 · Reply

RunnerSignals Feb. 24 at 3:04 PM

Top Stocks Hitting 52-Week High $AXTI $IPG $GNFT $TSM $FRO

0 · Reply

Noobnr1 Feb. 20 at 12:49 PM

$GNFT 🚀🚀🚀

0 · Reply

ThunderTheater Dec. 26 at 5:29 PM

$GNFT Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Execution quality will determine whether momentum is sustainable.

0 · Reply

BillionerOfKing Dec. 26 at 11:50 AM

$GNFT Current Stock Price: $0.00

0 · Reply

QuestCube Dec. 26 at 5:35 AM

$GNFT Upside exists, but only alongside disciplined prioritization and resource control. Cash generation will determine how self-sustaining growth becomes. If milestones track on schedule, sentiment can re-rate faster than fundamentals. Future returns will be dictated by execution quality, not headlines.

0 · Reply

judgeyoung2 Dec. 3 at 4:29 PM

$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.

0 · Reply

TwongStocks Nov. 20 at 5:03 PM

$GNFT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market https://ir.genfit.com/news-releases/news-release-details/genfit-announces-effectiveness-voluntary-delisting-american

0 · Reply

GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter

May 25, 2026, 12:00 PM EDT - 10 days ago

GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026

May 21, 2026, 12:00 PM EDT - 14 days ago

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

May 21, 2026, 12:00 PM EDT - 14 days ago

Genfit Earnings release: Q1 2026

May 11, 2026, 1:00 PM EDT - 24 days ago

GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents

Apr 24, 2026, 2:00 AM EDT - 6 weeks ago

Genfit Slides: Investor presentation

Apr 20, 2026, 12:00 PM EDT - 6 weeks ago

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

Apr 2, 2026, 12:30 PM EDT - 2 months ago

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Apr 2, 2026, 11:45 AM EDT - 2 months ago

Genfit Annual report: Q4 2025

Apr 2, 2026, 11:45 AM EDT - 2 months ago

Genfit Earnings release: Q4 2025

Mar 9, 2026, 1:00 PM EDT - 3 months ago

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

Feb 26, 2026, 11:45 AM EST - 3 months ago

Genfit Earnings release: Q4 2025

Feb 12, 2026, 12:35 PM EST - 4 months ago

GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales

Jan 7, 2026, 12:00 PM EST - 5 months ago

GENFIT Announces 2026 Financial Calendar

Dec 10, 2025, 12:00 PM EST - 6 months ago

GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy

Nov 27, 2025, 12:00 PM EST - 6 months ago

GENFIT Announces Appointment of new Chief Medical Officer

Nov 20, 2025, 12:10 PM EST - 7 months ago

GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update

Nov 20, 2025, 12:00 PM EST - 7 months ago

GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Nov 20, 2025, 12:00 PM EST - 7 months ago

Genfit Earnings release: Q3 2025

Nov 10, 2025, 1:45 AM EST - 7 months ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

Nov 10, 2025, 1:30 AM EST - 7 months ago

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025

2025-10-30T21:10:57.000Z - 7 months ago

Genfit announces intention to voluntarily delist ADSs from Nasdaq

Oct 30, 2025, 4:00 PM EDT - 7 months ago

GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market

Oct 28, 2025, 5:10 PM EDT - 7 months ago

GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025

2025-09-24T10:10:12.000Z - 9 months ago

Genfit price target lowered to $7 from $9 at H.C. Wainwright

Sep 22, 2025, 4:10 PM EDT - 9 months ago

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

Sep 22, 2025, 1:00 PM EDT - 9 months ago

Genfit Earnings release: Q2 2025

Sep 22, 2025, 1:00 PM EDT - 9 months ago

Genfit Earnings release: Q2 2025

Sep 19, 2025, 4:10 PM EDT - 9 months ago

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD

2025-08-19T10:10:33.000Z - 10 months ago

Genfit assumed with a Buy at H.C. Wainwright

Jul 8, 2025, 4:10 PM EDT - 11 months ago

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Jun 17, 2025, 2:30 PM EDT - 1 year ago

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

May 22, 2025, 4:10 PM EDT - 1 year ago

GENFIT Reports First Quarter 2025 Financial Information

May 22, 2025, 4:00 PM EDT - 1 year ago

Genfit Earnings release: Q1 2025

2025-05-20T20:20:25.000Z - 1 year ago

Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement

May 20, 2025, 4:10 PM EDT - 1 year ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 14, 2025, 4:10 PM EDT - 1 year ago

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 7, 2025, 4:10 PM EDT - 1 year ago

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 5, 2025, 1:30 AM EDT - 1 year ago

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Apr 29, 2025, 3:10 PM EDT - 1 year ago

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

Apr 28, 2025, 4:10 PM EDT - 1 year ago

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Apr 24, 2025, 4:10 PM EDT - 1 year ago

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Apr 24, 2025, 11:40 AM EDT - 1 year ago

Genfit Annual report: Q4 2024

Apr 24, 2025, 11:40 AM EDT - 1 year ago

Genfit Earnings release: Q4 2024

Apr 24, 2025, 11:40 AM EDT - 1 year ago

Genfit Earnings release: Q4 2024

Mar 20, 2025, 5:10 PM EDT - 1 year ago

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Mar 10, 2025, 5:10 PM EDT - 1 year ago

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Feb 27, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Feb 21, 2025, 2:30 AM EST - 1 year ago

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

Feb 14, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

2025-02-10T10:31:19.000Z - 1 year ago

Genfit announces final terms for dual proposal to 2025 Oceanes holders

Feb 6, 2025, 4:10 PM EST - 1 year ago

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Jan 30, 2025, 2:40 AM EST - 1 year ago

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Jan 29, 2025, 4:10 PM EST - 1 year ago

GENFIT Announces 2025 Financial Calendar

Jan 13, 2025, 4:10 PM EST - 1 year ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Dec 12, 2024, 7:00 AM EST - 1 year ago

Genfit Slides: Corporate Presentation

Nov 13, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Nov 7, 2024, 4:10 PM EST - 1 year ago

GENFIT Reports Third Quarter 2024 Financial Information

Nov 7, 2024, 3:00 AM EST - 1 year ago

Genfit Earnings release: Q3 2024

Sep 23, 2024, 1:30 AM EDT - 1 year ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Sep 20, 2024, 11:40 AM EDT - 1 year ago

Genfit Earnings release: Q2 2024

2024-07-26T11:47:55.000Z - 2 years ago

Genfit announces positive CHMP opinion for Ipsen’s Iqirvo

Jul 26, 2024, 7:45 AM EDT - 2 years ago

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

2024-06-17T20:31:01.000Z - 2 years ago

Genfit: New EASL-EASD-EASO guidelines include NIS2+

Jun 17, 2024, 4:10 PM EDT - 2 years ago

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

2024-06-11T11:43:31.000Z - 2 years ago

Genfit price target raised to $13 from $11 at H.C. Wainwright

2024-06-10T21:55:00.000Z - 2 years ago

Genfit SA (ADR) trading resumes

Jun 10, 2024, 5:22 PM EDT - 2 years ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Jun 10, 2024, 5:08 PM EDT - 2 years ago

US FDA approves Genfit and Ipsen's liver disease drug

2024-06-10T20:42:03.000Z - 2 years ago

Genfit SA (ADR) trading halted, news pending

May 29, 2024, 4:10 PM EDT - 2 years ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

May 22, 2024, 12:05 PM EDT - 2 years ago

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

May 14, 2024, 4:10 PM EDT - 2 years ago

GENFIT Reports First Quarter 2024 Financial Information

May 14, 2024, 1:00 AM EDT - 2 years ago

Genfit Earnings release: Q1 2024

Apr 25, 2024, 4:10 PM EDT - 2 years ago

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Apr 15, 2024, 4:10 PM EDT - 2 years ago

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Apr 5, 2024, 1:00 AM EDT - 2 years ago

Genfit Slides: Corporate Presentation

Apr 4, 2024, 1:00 AM EDT - 2 years ago

Genfit Annual report: H2 2023

Apr 4, 2024, 1:00 AM EDT - 2 years ago

Genfit Annual report: H2 2023

Dec 12, 2023, 1:00 AM EST - 2 years ago

Genfit Slides: Corporate Presentation

2023-11-14T00:53:41.000Z - 2 years ago

Ipsen, Genfit announce full results from pivotal Phase III ELATIVE trial

Nov 9, 2023, 1:00 AM EST - 2 years ago

Genfit Earnings release: Q3 2023

2023-09-26T20:14:02.000Z - 2 years ago

Genfit publishes NIS4 NASH diagnostic technology data

Sep 20, 2023, 4:15 PM EDT - 2 years ago

Genfit Earnings Call Transcript: H1 2023

Sep 20, 2023, 4:15 PM EDT - 2 years ago

Genfit Earnings release: H1 2023

Sep 12, 2023, 1:00 AM EDT - 2 years ago

Genfit Slides: Corporate Presentation

2023-09-11T12:58:03.000Z - 2 years ago

Genfit price target lowered to EUR 7 from EUR 9 at Guggenheim

2023-08-10T21:02:07.000Z - 3 years ago

Genfit publishes new data on clinical performance of NIS2+ in older patients

Thorilium Apr. 25 at 7:07 AM

$GNFT This happens when a stock is rejected This did not happened with $ABVEF Think why is this! Because the race is still open, just a few missed corners.

0 · Reply

Rickycello Feb. 25 at 12:10 PM

$GNFT bear: 6.78€ base: 10.26€ bull: 15€ Intrinsic value: 3.93€ Sell price target: 10.51€ (12% margin) Reward / risk: 0.39 Risk / reward: 2.54

0 · Reply

Alexis348 Feb. 24 at 6:33 PM

$GNFT what's everyones thought on this. How far up can it go?!

1 · Reply

RunnerSignals Feb. 24 at 3:04 PM

Top Stocks Hitting 52-Week High $AXTI $IPG $GNFT $TSM $FRO

0 · Reply

Noobnr1 Feb. 20 at 12:49 PM

$GNFT 🚀🚀🚀

0 · Reply

ThunderTheater Dec. 26 at 5:29 PM

0 · Reply

BillionerOfKing Dec. 26 at 11:50 AM

$GNFT Current Stock Price: $0.00

0 · Reply

QuestCube Dec. 26 at 5:35 AM

0 · Reply

judgeyoung2 Dec. 3 at 4:29 PM

$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.

0 · Reply

TwongStocks Nov. 20 at 5:03 PM

0 · Reply

Doozio Nov. 20 at 2:36 AM

$GNFT 🐒🍌🧠⏰♾️

0 · Reply

BLD33 Nov. 11 at 3:24 PM

$GNFT 9 days of covering !!!

0 · Reply

twincam Nov. 10 at 11:29 PM

$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.

0 · Reply

Noobnr1 Nov. 10 at 5:47 PM

$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂

0 · Reply

Rickycello Nov. 10 at 6:56 AM

$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-enters-research-collaboration-everzom-advance-exosome

0 · Reply

Rickycello Nov. 10 at 6:55 AM

$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-presents-promising-new-preclinical-data-ntzg1090n

0 · Reply

BillionerOfKing Nov. 3 at 1:27 PM

$GNFT Current Stock Price: $3.85 No options data available.

0 · Reply

Rickycello Oct. 28 at 9:45 PM

$GNFT !!! Mark the day!!! "...announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025."

0 · Reply

abbk Oct. 24 at 4:42 PM

$GNFT not trading? no movement

0 · Reply

Amb8675309 Oct. 9 at 5:36 PM

$GNFT what’s with the “new orders not being accepted at this time” message

0 · Reply

Market Cap	242.62M
Revenue (ttm)	76.76M
Net Income (ttm)	1.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2.12%
Debt to Equity Ratio	0.14

Volume	56,900
Avg Vol	11,412
Day's Range	N/A - N/A
Shares Out	50.03M
Stochastic %K	93%
Beta	1.09
Analysts	Strong Sell
Price Target	$7.50